Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Update

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 169,677 shares, a decline of 72.9% from the May 31st total of 625,772 shares. Based on an average daily volume of 2,555,159 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.0% of the company’s stock are short sold.

Jupiter Neurosciences Stock Up 19.6%

Shares of NASDAQ JUNS opened at $0.28 on Friday. Jupiter Neurosciences has a 52 week low of $0.17 and a 52 week high of $3.33. The stock has a market capitalization of $10.27 million, a price-to-earnings ratio of -1.05 and a beta of 1.71. The firm has a 50-day simple moving average of $0.30 and a 200-day simple moving average of $0.56.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.23 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in JUNS. Yorkville Advisors Global LP acquired a new position in Jupiter Neurosciences in the fourth quarter valued at $135,000. Geode Capital Management LLC increased its holdings in Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after buying an additional 28,826 shares in the last quarter. Vestor Capital LLC grew its stake in Jupiter Neurosciences by 144,607.2% in the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after acquiring an additional 970,314 shares during the last quarter. Finally, Allen Capital Group LLC acquired a new position in shares of Jupiter Neurosciences in the fourth quarter worth $31,000.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.